Our top pick for
MoSys Inc is a semiconductors business based in the US. MoSys shares (MOSY) are listed on the NASDAQ and all prices are listed in US Dollars. MoSys employs 24 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$6.29|
|52-week range||$1.36 - $10.75|
|50-day moving average||$5.38|
|200-day moving average||$5.22|
|Wall St. target price||$1.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.92|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-21)||8.26%|
|1 month (2021-09-28)||18.90%|
|3 months (2021-07-28)||32.98%|
|6 months (2021-04-28)||57.25%|
|1 year (2020-10-28)||265.70%|
|2 years (2019-10-28)||174.67%|
|3 years (2018-10-26)||2,275.38%|
|5 years (2016-10-28)||949.91%|
Valuing MoSys stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of MoSys's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
MoSys's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.3 million.
The EBITDA is a measure of a MoSys's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$6.1 million|
|Gross profit TTM||$4.5 million|
|Return on assets TTM||-17.08%|
|Return on equity TTM||-30.61%|
|Market capitalisation||$49.2 million|
TTM: trailing 12 months
There are currently 64,376 MoSys shares held short by investors – that's known as MoSys's "short interest". This figure is 60.5% down from 162,939 last month.
There are a few different ways that this level of interest in shorting MoSys shares can be evaluated.
MoSys's "short interest ratio" (SIR) is the quantity of MoSys shares currently shorted divided by the average quantity of MoSys shares traded daily (recently around 919657.14285714). MoSys's SIR currently stands at 0.07. In other words for every 100,000 MoSys shares traded daily on the market, roughly 70 shares are currently held short.
However MoSys's short interest can also be evaluated against the total number of MoSys shares, or, against the total number of tradable MoSys shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case MoSys's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 MoSys shares in existence, roughly 10 shares are currently held short) or 0.0074% of the tradable shares (for every 100,000 tradable MoSys shares, roughly 7 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against MoSys.
Find out more about how you can short MoSys stock.
We're not expecting MoSys to pay a dividend over the next 12 months.
MoSys's shares were split on a 1:20 basis on 27 August 2019. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your MoSys shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for MoSys shares which in turn could have impacted MoSys's share price.
Over the last 12 months, MoSys's shares have ranged in value from as little as $1.36 up to $10.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MoSys's is 2.1497. This would suggest that MoSys's shares are significantly more volatile than the average for this exchange and represent a higher risk.
MoSys, Inc. , together with its subsidiaries, operates as a semiconductor company in North America, Japan, Taiwan, and internationally. The company develops and sells integrated circuits (ICs) for high-speed cloud networking, communications, security appliance, video, monitor and test, and computing markets. It offers bandwidth engine ICs and programmable hyperspeed engine IC products under the Accelerator Engine name; quad partition rate SRAM memory devices; non-memory, high-speed serialization-deserialization interface, and physical layer devices; and virtual accelerator engines, such as graph memory engines and accelerator IPs. The company also serves data centers and other equipment providers, as well as their subsystem and component vendors; and original equipment manufacturers through direct sales personnel, sales representatives, and distributors. MoSys, Inc. was incorporated in 1991 and is headquartered in San Jose, California.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.